Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

GenVault (Carlsbad, CA) focused on room temperature biosample management, closed a $13M Series C financing. Participants included Montagu Newhall Associates, Domain Associates, QuestMark Partners and Cross Creek Capital.

Gemin X Pharmaceuticals (Malvern, PA) focused on developing novel treatments for cancer, closed a $38M Series C financing. Participants include Caxton Advantage Life Sciences Fund, Caxton Global, Sanderling Ventures, H.I.G. Ventures, CDP/Vantage Point, ProQuest, Merlin BioMed Group, HBM Partners, Canadian Medical Discoveries Fund, Ontario Teachers’ Pension Plan Board, SoftBank Life Science, Business Development Bank of […]

Syndexa Pharmaceuticals (Cambridge, MA) a metabolic drug discovery company, closed a $15M Series B financing. Participants include Yalcin Ayalsi.

Rox Medical (San Clemente, CA) medical device company focused on chronic obstructive pulmonary disease, closed a $35M Series C financing. Participants include Essex Woodlands Health Ventures, Domain Associates, Prism VentureWorks and Versant Ventures.

PhysioSonics (Seattle, WA) a developer of noninvasive neurologic products, closed a $4M Series A financing. Participants include Johnson & Johnson Development Corp.

Oncodesign (France) a CRO and provider of preclinical oncology services, closed a $4.7 million Series B financing. Participants include Vizille Capital Innovation and Avenir Enterprises.

TelaDoc Medical Services (Dallas, TX) a commercial stage company focused on providing around-the-clock access to telephone consults with primary care doctors who diagnose medical problems and prescribe medication, closed a $3M Series A financing. Participants include Trident Capital.

China Medicine On-Line (China) focused on building a nation-wide integrated network to provide tele-homecare and tele-healthcare services, closed an $8M series A financing. Participants include Infinity I-China Fund.

Inimex Pharmaceuticals (Canada) developer of medicines that use selective modulation of the innate immune response, closed a $22M Series B financing. Participants include Morningside Venture Investments, Astellas Venture Management, Advantage Life Science Fund, BC Advantage Funds, BDC Capital, British Columbia Discovery Fund, Canadian Medical Discovery Fund and Working Opportunity Fund.

Sinexus (Palo Alto, CA) developer of medical devices for the treatment of chronic sinusitis, closed a $20M Series B financing. Participants include PTV Sciences, Kleiner Perkins Caufield & Buyers and U.S. Venture Partners.

DFine (San Jose, CA) developer of electrosurgical systems for treating vertebral compression fractures, closed a $30M Series D financing. Participants include BBT Fund, Prospect Venture Partners and Vanguard Ventures.

Creabilis Therapeutics (Italy) dermatological drug start-up focused on psoriasis, dermatitis, and Behcet’s Disease, closed a $25M Series A financing. Participants include Sofinnova Partners and NeoMed Management.

Entellus Medical (Maple Grove, MN) developer of sinusitis treatment system, closed a $15M Series C financing. Participants include Montagu Newhall Associates, Split Rock Partners and SV Life Sciences.

« Previous Entries  Next Page »

to top of page...